Stuart Therapeutics, Inc.

About Stuart Therapeutics, Inc.

Stuart Therapeutics is a clinical-stage pharmaceutical company focused on developing a unique synthetic protein, PolyColTM, designed to target and repair disease-damaged helical collagen in the human body. Founded in 2018, the company aims to treat chronic eye diseases such as Dry Eye Disease, Glaucoma, Dry Age-Related Macular Degeneration, and Myopia, with a mission to preserve visual function and patients' futures.

Products & Services

PolyColTM Technology:A series of synthesized amino acid sequences designed to bind to and repair disease-damaged helical collagen in the extracellular matrix and membranes, targeting chronic eye diseases.

ST-100 (Vezocolmitide) Ophthalmic Solution:A novel candidate for treating Dry Eye Disease, currently in Phase III clinical trials.

Specialties

Chronic Eye Diseases Dry Eye Disease Glaucoma Dry Age-Related Macular Degeneration Myopia Collagen Mimetic Peptides Ophthalmic Drug Development

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Debt T: - FT: Debt	A: 5000000 MR: - FA: approximately $5.0 million FAN: 5000000	D: 2023-07-12 FD: 2023-07-12	1 investors

Debt Latest

2023-07-12

$5.0M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

E

Eric Schlumpf

President and CEO

S

Shawn DeLorey

Executive Vice President, Program Management

T

Tracy Valorie

Strategic Business Consultant

J

Jason Werner

Executive Chairman

R

Robert O. Baratta

Executive Chairman

L

Lukas Scheibler

R&D Professional

View 21 more team members with Pro

Unlock Full Team Directory

Recent News